High-dose pollen intralymphatic immunotherapy: Two RDBPC trials question the benefit of dose increase.
Allergy
; 77(3): 883-896, 2022 03.
Article
en En
| MEDLINE
| ID: mdl-34379802
ABSTRACT
BACKGROUND:
The same dosing schedule, 1000 SQ-U times three, with one-month intervals, have been evaluated in most trials of intralymphatic immunotherapy (ILIT) for the treatment of allergic rhinitis (AR). The present studies evaluated if a dose escalation in ILIT can enhance the clinical and immunological effects, without compromising safety.METHODS:
Two randomized double-blind placebo-controlled trials of ILIT for grass pollen-induced AR were performed. The first included 29 patients that had recently ended 3 years of SCIT and the second contained 39 not previously vaccinated patients. An up-dosage of 1000-3000-10,000 (5000 + 5000 with 30 minutes apart) SQ-U with 1 month in between was evaluated.RESULTS:
Doses up to 10,000 SQ-U were safe after recent SCIT. The combined symptom-medication scores (CSMS) were reduced by 31% and the grass-specific IgG4 levels in blood were doubled. In ILIT de novo, the two first patients that received active treatment developed serious adverse reactions at 5000 SQ-U. A modified up-dosing schedule; 1000-3000-3000 SQ-U appeared to be safe but failed to improve the CSMS. Flow cytometry analyses showed increased activation of lymph node-derived dendritic but not T cells. Quality of life and nasal provocation response did not improve in any study.CONCLUSION:
Intralymphatic immunotherapy in high doses after SCIT appears to further reduce grass pollen-induced seasonal symptoms and may be considered as an add-on treatment for patients that do not reach full symptom control after SCIT. Up-dosing schedules de novo with three monthly injections that exceeds 3000 SQ-U should be avoided.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Rinitis Alérgica Estacional
/
Rinitis Alérgica
Tipo de estudio:
Clinical_trials
Límite:
Humans
Idioma:
En
Año:
2022
Tipo del documento:
Article